Τόμος 20 (2002) – Τεύχος 1 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 20 (2002) – Issue 1 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Φραγκίσκη Ανθούλη-Αναγνωστοπούλου

Σχολή Επαγγελμάτων Υγείας και Πρόνοιας, Τεχνολογικό Εκπαιδευτικό Ίδρυμα (ΤΕΙ), Αθήνα, Ελλάς

F. A. Anthouli-Anagnostopoulou

General Department of Essential Medical Sub­jects, Faculty of Health and Caring Professions, Technological Educational Institution, Athens, Greece

2. Cornelis F.: Susceptibility genes in rheumatoid arthritis. Curr. Dir. Autoimmun. 3: 112-132 (2001)

3. Alarcon G.S.: Is rheumatoid arthritis in African descendants from North and South America the same? Semin. Arthritis Rheum. 31: 143-145 (2001)

4. Mc Queen F.M., Stewart N., Crabble J., et al.: Magnetic reso­nance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann. Rheumatic Dis. 57: 350-356 (1996)

5. Mc Gonagle D., Conaghan, P.G., O’Connor P., et al: The relationship between synovitis and bone changes in early un­treated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum. 42: 1706-1711 (1999)

6. Devlin J., Gough A., Huissoon A., Perkins P., Jubb R., Emery P.: The outcome of knee synovitis in early arthritis provides guidelines for management. Clin. Rheumatol. 19: 82-85 (2000)

7. Wolfe F., Sharp., J.T.: Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum. 41: 1571-1582 (1998)

8. Silman A.J., Mac Gregor A.J., Thomson W., et al.: Twin con­cordance rates for rheumatoid arthritis: results from a national study. Br. J. Rheumatol. 32: 903-907 (1993)

9. Mac Grecgor A.J., Snieder H., Rigby A.S., et al.: Characteriz­ing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43: 30-37 (2000)

10. Mac Gregor A.J., Bamber S., Carthy D., et al.: Heterogenity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis. Br. J. Rheumatol. 34: 215-220 (1995)

11. Ollier W.E., Mac Gregor A.: Genetic epidemiology of rheu­matoid disease. Br. Med. Bull. 51: 267-285 (1995)

12. Seldin M.F., Amos C.I., Ward R., Gregersen P.K.: The ge­netics revolution and the assault on rheumatoid arthritis. Arthritis Rheum. 42: 1071-1079 (1999)

13. Girard J.P., Springer T.A.: High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today 16: 449-457 (1995)

14. Shiozawa S., Shiozawa K., Fujita T.: Morphologic observa­tions in the early phase of the cartilage-pannus junction: light and electron microscopic studies of active cellular pannus. Arthritis Rheum. 26: 472-478 (1983)

15. Kobayashi I., Ziff M.: Electron microscopic studies of the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum. 18: 475-483 (1975)

16. Υamanishi Y., Firestein G.S.: Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. North Am. 27: 355-371 (2001)

17. VanderBorght A., Geusens P., Raus J., Stinissen P.: The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin. Atrhritis Rheum. 31: 160-175 (2001)

18. Sinigaglia F., Nagy Z.A.: Structural basis for the HLA-DR association of rheumatoid arthritis. Curr. Dir. Autoimmun. 3: 36-50 (2001)

19. Weyand C.M., Goronzy J.J.: Association of MHC and rheu­matoid arthritis. HLA polymorphisms in phenotypic variants of rheumatoid arthritis. Arthritis Res. 2: 212-216 (2000)

20. Goronzy J.J., Weyyand C.M.: T cell homeostasis and autoreactivity in rheumatoid arthritis. Curr. Dir. Autoimmun. 3: 112-132 (2001)

21. Arend W.P.: The innate immune system in rheumatoid ar­thritis. Arthritis Rheum. 44: 2224-2234 (2001)

22. La Cava A., Sarvetnick N.: The role of cytokines in autoim­munity. Curr. Dir. Autoimmun. 1: 56-71 (1999)

23. Feldmannn M., Brennan F.M., Foxwell B.M., Maini R.N.: The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr. Dir. Autoimmun. 3: 188-199 (2001)

24. Chu C.Q., Field M., Feldmann M., Maini R.N.: Localization of tumor necrosis factor alpha in synovial tissues and at the carti­lage-pannus junction in patients with rheumatoid arthritis. Arthri­tis Rheum. 34: 1125-1132 (1991)

25. Cope A.P., Aderka D., Doherty M., et al.: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 35: 1160-1169 (1992)

26. Arend W.P., Malyak M., Smith M.F, et al.: Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1receptors in synovial fluids. J. Immunol. 153: 4766-4774 (1994)

27. Firestein G.S., Berger A.E., Tracy D.E., et al.: IL-1 receptor antagonist protein production and gene expression in rheuma­toid arthritis and osteoarthritis synovium. J. Immunol. 143: 1054-1062 (1992)

28. Joosten L.A., Helsen M.M., van de Loo F.A., van den Berg W.B.: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 39: 797-809 (1996)

29. Godessart N., Kunkel S.L.: Chemokines in autoimmune disesse. Curr. Opin. Immunol. 13: 670-675 (2001)

30. Martel-Pelletier J., Welsch D.J., Pelletier J.P.: Metalloprote­ases and inhibitors in arthritic diseses. Best Pract. Res. Clin. Rheumatol. 15: 805-829 (2001)

31. Johnson B.A., Haines G.K., Harlow L.A., Koch A.E.: Adhe­sion molecule expression in human synovial tissue. Arthritis Rheum. 36: 137-146 (1993)

32. Koch A.E.: Angiogenesis: implications for rheumatoid arthri­tis. Arthritis Rheum. 41: 951-962 (1998)

33. Albano S.A., Santana-Sahagun E., Weisman M.H.: Cigarette smoking and rheumatoid arthritis. Semin. Arthritis Rheum. 31: 146-149 (2001)

34. Scott T.E.: Pharmaceutical agents for the treatment of rheumatoid arthritis. Manag. Care 10(7 Suppl.): 2-9 (2001)

35. Quinn M.A., Conaghan P.G., Emery P.: The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 40: 1211-1220 (2001)

36. van der Heide A., Jacobs J.W., Bijlsma J.W., et al.: The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann. Intern. Med. 124: 699-707 (1996)

37. Cooper N.J.: Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39: 28-33 (2000)

38. Reilly P.A., Cosh J.A., Maddison P.J., Rasker J.J., Silman A.: Mortality and survival in rheumatoid arthritis: a 35 year pro­spective study of 100 patients. Ann. Rheumatic Dis. 49: 363-369 (1990)

39. Felson D.T., Anderson J.J., Boers M., et al.: American Col­lege of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38: 727-735 (1995)

40. van der Heijde D.M., van’t Hof M., van Riel P.L., van de Putte L.B.: Development of disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol. 20: 579-581 (1993)

41. Doyle J.J.: Economic and quality-of-life impact of rheumatoid arthritis. Manag. Care 10(7 Suppl.): 15-18 (2001)

42. Larsen A.: A radiological method for grading the severity of rheumatoid arthritis. Scand. J. Rheumatol. 4: 225-233 (1975)

43. Sharp J.T.: Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum. 221-229 (1989)

44. St. Clair E.W.: therapy of rheumatoid arthritis: new develop­ments and trends. Curr. Rheumatol. Rep. 1: 149-156 (1999)

45. Pincus T., Marcum S.B., Callahan L.F.: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II, second line drugs and prednisone. J. Rheumatol. 19: 1885-1894 (1992).

46. Grove M.L., Hassel A.B., Hay E.M., Shadforth M.F.: Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 94: 309-319 (2001)

47. Mulherin D., Fitzgerald O., Bresnihan B.: Clinical improve­ment and radiological deterioration in rheumatoid arthritis: evi­dence that the pathogenesis of synovial inflammation and ar­ticular erosion may differ. Br. J. Rheumatol. 35: 1263-1268 (1996)

48. Weinblatt M.E., Maier A.L., Frasr P.A., Coblyn J.S.: Long­term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J. Rheumatol. 25: 238-242 (1998)

49. Weinblatt M.E., Kaplan H., Germain B.F., et al.: Meth­otrexate in rheumatoid arthritis. A five-year prospective multi­center study. Arthritis Rheum. 37: 1492-1498 (1994)

50. No authors listed.: Treatment of rheumatoid arthritis: un­known long-term effects. Rrescrire Int. 10: 55-61 (2001)

51. Willkens R.F., Urowitz M.B., Stablein D.M., et al.: Compari­son of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum. 35: 849-856 (1992)

52. Kremer J.M.: Combination DMARD therapy for rheumatoid arthritis. Manag. Care 10 (7 Suppl.): 10-14 (2001)

53. Tugwell P., Pincus T., Yocum D., et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthri­tis. N. Eng. J. Med. 333: 137-141 (1995)

54. Lipsky P.E., van der Heijde D.M., St. Clair E.W., et al.: In­fliximab and methotrexate in the treatment of rheumatoid arthri­tis. N. Eng. J. Med. 343: 1594-1602 (2000)

55. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al.: A trial of etanecerpt, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Eng. J. Med. 253-259 (1999)

56. Weinblatt M.E., Kremer J.M., Coblyn J.S., et al.: Pharma­cokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 42: 1322-1328 (1999)

57. O’ Dell J.R., Haire C.E., Erikson N., et al.: Treatment of rheumatoid arthritis with methoterxate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Eng. J. Med. 334: 1287-1291 (1996)

58. Boers M., Verhoeven A.C., Markusse H.M., et al.: Random­ized comparison of combined step-down prednisolone, meth­otrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet 350: 309-318 (1997)

59. Mottonen T., Hannonen P., Leirisalo-Repo M., et al.: Com­parison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 353: 1568-1573 (1999)

60. Ηaraoui B., Strand V., Keystone E.: Biologic agents in the treatment of rheumatoid arthritis. Curr. Pharm. Biotechnol. 1: 217-233 (2000)

61. Cherwinski H.M., Cohn R.G., Cheung P., et al.: The immu­nosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exper. Ther. 275: 1043-1049 (1995)

62. Tugwell P., Wells G., Strand V., et al.: Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with meth­otrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum. 43: 506-514 (2000)

63. Kremer J.M., Caldwell J.R., Cannon G.W., et al.: The com­bination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: a double-blind placebo controlled study. Arthritis Rheum. 44: S 224(abstr.) (2000)

64. Coblyn J.S., Shadick N., Helfgott S.: Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis Rheum. 44: 1048-1051 (2001)

65. Skapenko A., Kalden J.R., Sculze-Koops H.: Treatment of rheumatoid arthritis in the third millennium. Scand. J. Rheuma­tol. 30: 249-254 (2001)

66. Taylor P.C., Williams R.O., Maini R.N.: Anti-TNF alpha therapy in rheumatoid arthritis–current and future directions. Curr. Dir. Autoimmun. 2: 83-102 (2000)

67. Freeman B.D., Buchman T.G.: Interleukin-1 receptor an­tagonist as therapy for inflammatory disorders. Expert Opin. Biol. Ther. 1: 301-308 (2001)

68. Alldred A.: Etanecerpt in rheumatoid arthritis. Expert Opin. Pharmacother. 2: 1137-1148 (2001)

69. Moreland L.W., Schiff M.H., Baumgartner S.W., et al.: Etanecerpt therapy in rheumatoid arthritis: a randomized, con­trolled trial. Ann. Intern. Med. 130: 478-486 (1999)

70. Barton J.M., Martin R.W., Fleischmann R.M., et al.: A com­parison of etanecerpt and methotrexate in patients with early rheumatoid arthritis. N. Eng. J. Med. 343: 1586-1593 (2000)

71. Zelter R., Valle L., Tanck C., Holyst M.M., Ritchlin C., Gas­pari A.A.: Clinical, histological, and immunophenotypic charac­teristics of injection site reactions associated with etanecerpt: Fc fusion protein. Arch. Dermatol. 137: 893-899 (2001)

72. Shakoor N., Michalska M., Harris C.A., block J.A.: Drug-induced systemic lupus erythematosus associated with etaner­cept therapy. Lancet 359: 579-580 (2002)

73. Karanaugh A., St. Clair E.W., Mc Cune W.J., Braakman T., Lipsky P.: Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. 27: 841-850 (2000)

74. Valle E., Gross M., Bickston S.J.: Infliximab. Expert Opin. Pharmacother. 2: 1015-1025 (2001)

75. Robinson W.H., Genovese M.C., Moreland L.W.: Demyeli­nating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. 44: 1977-1983 (2001)

76. Tidow-Kebritchi S., Morbahan S.: Effects of diets containing fish oil and vitamin E on rheumatoid arthritis. Nutr. Rev. 59: 335-338 (2001)